| 4 | 1/1 | 返回列表 |
| 查看: 625 | 回復: 3 | ||
| 本帖產(chǎn)生 1 個 翻譯EPI ,點擊這里進行查看 | ||
yin198716新蟲 (正式寫手)
|
[求助]
求助翻譯
|
|
| Tumor angiogenesis is essential for tumor growth and metastasis and is triggered by a variety of proangiogenic factors, regulated by many angiogenic pathways. The most important and best characterized is the VEGF pathway . Blockade of VEGF signaling inhibits tumor angiogenesis and growth in various preclinical models and having systemic effects . The effect of anti-VEGF strategy has been validated in randomized phase III clinical trials. Disruption of VEGF signaling by using bevacizumab, a humanized anti-human VEGF antibody or sorafenib and sunitinib, 2 small chemical inhibitors of receptor-tyrosine kinases (RTK) including VEGF receptors have yielded a significant improvement in progression-free survival but rarely in overall survival for patients with several types of cancers including metastatic colorectal cancer , advanced non–small cell lung cancer , metastatic breast cancer , advanced clear-cell renal-cell carcinoma and advanced hepatocellular carcinoma . |


木蟲 (小有名氣)
|
Tumor angiogenesis is essential for tumor growth and metastasis and is triggered by a variety of proangiogenic factors, regulated by many angiogenic pathways. 腫瘤血管新生是腫瘤生長和轉(zhuǎn)移所必需的,它由多種促血管形成因子觸發(fā)并受多種血管新生通路調(diào)控。 The most important and best characterized is the VEGF pathway . 最重要和最有特點的就是VEGF通路。 Blockade of VEGF signaling inhibits tumor angiogenesis and growth in various preclinical models and having systemic effects . 在多種臨床前模型中,阻斷VEGF信號會抑制腫瘤血管新生和腫瘤生長,并且會有系統(tǒng)性的效應。 The effect of anti-VEGF strategy has been validated in randomized phase III clinical trials. 抗VEGF策略的作用在隨機III期臨床試驗中得到鞏固。 Disruption of VEGF signaling by using bevacizumab, a humanized anti-human VEGF antibody or sorafenib and sunitinib, 2 small chemical inhibitors of receptor-tyrosine kinases (RTK) including VEGF receptors have yielded a significant improvement in progression-free survival but rarely in overall survival for patients with several types of cancers including metastatic colorectal cancer , advanced non–small cell lung cancer , metastatic breast cancer , advanced clear-cell renal-cell carcinoma and advanced hepatocellular carcinoma . 用貝伐單抗(人源化的抗VEGF抗體)或用索拉非尼和舒尼替尼(受體絡氨酸激酶的兩種化學抑制劑) 破壞VEGF信號,可以顯著改善無進展生存期,但對同時患有多種癌癥病人的總體存活率的改善并不大,包括轉(zhuǎn)移性結(jié)直腸癌、晚期非小細胞肺癌、轉(zhuǎn)移性乳腺癌、晚期透明性腎細胞癌和晚期肝癌。 收錄到淘貼專輯 |

新蟲 (正式寫手)

| 4 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 370求調(diào)劑 +3 | 080700調(diào)劑 2026-03-30 | 3/150 |
|
|---|---|---|---|---|
|
[考研] 食品工程專碩一志愿中海洋309求調(diào)劑 +5 | 小張zxy張 2026-03-26 | 10/500 |
|
|
[考研] 一志愿 南京航空航天大學 ,080500材料科學與工程學碩 +3 | @taotao 2026-03-30 | 3/150 |
|
|
[考研] 311求調(diào)劑一志愿合肥工業(yè)大學 +3 | 秋二十二 2026-03-30 | 3/150 |
|
|
[考研] 抱歉 +4 | 田洪有 2026-03-30 | 4/200 |
|
|
[考研] 求收留 +6 | 1943443204 2026-03-28 | 6/300 |
|
|
[考研] 279求調(diào)劑 +12 | j的立方 2026-03-29 | 12/600 |
|
|
[考研] 085600 286分 材料求調(diào)劑 +11 | 麻辣魷魚 2026-03-27 | 12/600 |
|
|
[考研] 08工科,295,接受跨專業(yè)調(diào)劑 +3 | lmnlzy 2026-03-30 | 3/150 |
|
|
[考研] 324求調(diào)劑 +9 | hanamiko 2026-03-26 | 11/550 |
|
|
[考研] 311求調(diào)劑 +10 | lin0039 2026-03-26 | 10/500 |
|
|
[考研] 318一志愿吉林大學生物與醫(yī)藥 求調(diào)劑 +5 | 篤行致遠. 2026-03-28 | 5/250 |
|
|
[考研] 總分293求調(diào)劑 +8 | 加一一九 2026-03-25 | 11/550 |
|
|
[考研] 一志愿華理,數(shù)一英一285求A區(qū)調(diào)劑 +8 | AZMK 2026-03-25 | 12/600 |
|
|
[考研] 070300求調(diào)劑306分 +4 | 26要上岸 2026-03-27 | 4/200 |
|
|
[考研] 調(diào)劑 +3 | 好好讀書。 2026-03-28 | 3/150 |
|
|
[考研] 085602 307分 求調(diào)劑 +7 | 不知道叫什么! 2026-03-26 | 7/350 |
|
|
[考研] 0856調(diào)劑 +5 | 求求讓我有書讀?/a> 2026-03-26 | 6/300 |
|
|
[考研] 085600,材料與化工321分調(diào)劑 +4 | 大饞小子 2026-03-27 | 6/300 |
|
|
[考研] 309求調(diào)劑 +4 | gajsj 2026-03-25 | 5/250 |
|